Statement for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation

The statement for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and dabigatran questions and answers are available below.

Dabigatran etexilate (Pradaxa®) and rivaroxaban (Xarelto®)

Healthcare Improvement Scotland has been providing national leadership and support for safe and effective use of the new oral anticoagulants, dabigatran etexilate (Pradaxa®) and rivaroxaban (Xarelto®) in NHSScotland via the development of a national statement on their use.

The statement identifies those patient groups that should be considered for dabigatran, rivaroxaban or existing anticoagulants, such as warfarin.

The statement has been issued via each NHS boards’ Area Drug and Therapeutic Committee (ADTC).

Further information

Share this content

Published Date: 30 April 2012